|  | | Latest Updates | | | |  | Bictegravir Approved for Initial ART, in Combination with TAF/FTC, posted April 11, 2018. | | | | Bictegravir/TAF/FTC for Women, posted April 11, 2018. | | | | Immediate ART Initiation Improves Time to Viral Suppression, posted April 11, 2018. | | | | Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study, posted April 11, 2018. | | | | Naltrexone Improves Virologic Suppression, posted April 11, 2018. | | | | Ibalizumab Approved for Persons with Multidrug Resistant HIV, posted April 11, 2018. | | | | Undetectable=Untransmittable: Effective HIV Treatment Prevents HIV Transmission, posted December 14, 2017. | | | | On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen, posted September 28, 2017. | | | | Bictegravir in Initial Therapy, posted September 28, 2017. | | | | Doravirine in Initial Therapy: DRIVE-AHEAD Study, posted September 28, 2017. | | | | CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment, posted April 14, 2017. | | | | CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison, posted April 14, 2017. | | | | CROI 2017: Dolutegravir in 2-Drug Simplification Studies, posted April 14, 2017. | | | | CROI 2017: Failure of Dolutegravir Monotherapy, posted April 14, 2017. | |
|
| | Archive | | | | | PrEP Uptake by Sex, Race, and Age, posted September 27, 2016. | | | | RAPID: Immediate ART Initiation, posted September 27, 2016. | | | | Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk; also a Word on HPTN 052, posted September 27, 2016. | | | | ART in Acute HIV--Decreasing HIV DNA, posted September 27, 2016. | | | | Improvements in ART and Viral Suppression Rates in the United States, posted September 27, 2016. | | | | HIV in Indiana, posted September 27, 2016. | | | | PrEP: Bone Density Improves after Stopping TDF/FTC, posted May 3, 2016. | | | | Use of Dolutegravir in Dialysis, posted May 3, 2016. | | | | TAF/FTC Coformulation Approved, posted April 26, 2016. | | | | Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy, posted April 11, 2016. | | | | Switching from TDF/FTC to TAF/FTC, posted March 17, 2016. | | | | Tissue Levels of TAF: Too Low for PrEP?, posted March 17, 2016. | | | | FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics, posted March 17, 2016. | | | | TAF: New Data on Tenofovir Alafenamide Fumarate, posted October 1, 2015. | | | | START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV, posted October 1, 2015. | | | | Pyrimethamine Availability, posted October 1, 2015. | | | | Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression, posted October 1, 2015. | | | | Adult and Adolescent Guidelines: Major Changes, posted April 28, 2015. | | | | Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients, posted April 15, 2015. | | | | Testosterone Therapy in HIV-Infected Men: Suboptimal Testing for Diagnosis and Monitoring, posted April 15, 2015. | | | | Switch to TDF/FTC from ABC/3TC Lowers Lipids, posted March 17, 2015. | | | | Tenofovir-Containing ART as HBV Prophylaxis, posted March 17, 2015. | | | | HIV PrEP and Incident HCV Infection, posted March 17, 2015. | | | | Drug-Drug Interactions: Tenofovir with Boosted PI + Ledipasvir, posted March 17, 2015. | | | | Drug-Drug Interactions: Aluminum- and Magnesium-Containing Antacids Not Recommended with Raltegravir, posted March 17, 2015. | | | | Two New Boosted-PI Coformulations, posted February 15, 2015. | |
|
|
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2018, Regents of the University of California.